Peter M.A. Calverley

39.0k total citations · 16 hit papers
258 papers, 25.6k citations indexed

About

Peter M.A. Calverley is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services. According to data from OpenAlex, Peter M.A. Calverley has authored 258 papers receiving a total of 25.6k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Pulmonary and Respiratory Medicine, 145 papers in Physiology and 13 papers in Emergency Medical Services. Recurrent topics in Peter M.A. Calverley's work include Chronic Obstructive Pulmonary Disease (COPD) Research (216 papers), Asthma and respiratory diseases (129 papers) and Respiratory Support and Mechanisms (124 papers). Peter M.A. Calverley is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (216 papers), Asthma and respiratory diseases (129 papers) and Respiratory Support and Mechanisms (124 papers). Peter M.A. Calverley collaborates with scholars based in United Kingdom, United States and Germany. Peter M.A. Calverley's co-authors include Jørgen Vestbo, Klaus F. Rabe, Bartolomé R. Celli, Christine Jenkins, Stephen I. Rennard, Julie Yates, Emiel F.�M. Wouters, Antonio Anzueto, William MacNee and Àlvar Agustí and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Peter M.A. Calverley

248 papers receiving 24.8k citations

Hit Papers

Global Strategy for the Diagnosis, Management, and Preven... 2003 2026 2010 2018 2007 2010 2003 2010 2010 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
    2007 3.9k citations Klaus F. Rabe, Antonio Anzueto et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
    2010 2.1k citations Jørgen Vestbo, Hana Müllerová et al. profile →
  3. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    2003 894 citations Peter M.A. Calverley, Jørgen Vestbo et al. profile →
  4. Characterisation of COPD heterogeneity in the ECLIPSE cohort
    2010 822 citations Àlvar Agustí, Peter M.A. Calverley et al. profile →
  5. Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
    2010 726 citations Àlvar Agustí, Peter M.A. Calverley et al. American Journal of Respiratory and Critical Care Medicine profile →
  6. Changes in Forced Expiratory Volume in 1 Second over Time in COPD
    2011 680 citations Jørgen Vestbo, Julie Yates et al. profile →
  7. Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
    2012 620 citations Àlvar Agustí, Stephen I. Rennard et al. profile →
  8. The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide
    2007 601 citations Jadwiga A. Wedzicha, Peter M.A. Calverley et al. American Journal of Respiratory and Critical Care Medicine profile →
  9. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    2009 575 citations Peter M.A. Calverley, Klaus F. Rabe et al. profile →
  10. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
    2003 558 citations Peter M.A. Calverley et al. European Respiratory Journal profile →
  11. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study
    2008 541 citations Bartolomé R. Celli, Julie A. Anderson et al. American Journal of Respiratory and Critical Care Medicine profile →
  12. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
    2017 452 citations Jadwiga A. Wedzicha, Marc Miravitlles et al. European Respiratory Journal profile →
  13. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
    2014 406 citations Kay Tetzlaff, Ronald Dahl et al. profile →
  14. Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease
    2012 313 citations Bartolomé R. Celli, Julie Yates et al. American Journal of Respiratory and Critical Care Medicine profile →
  15. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
    2016 312 citations Jørgen Vestbo, Julie A. Anderson et al. profile →
  16. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
    2018 302 citations Peter M.A. Calverley, Stephen I. Rennard et al. profile →

Peers

Peter M.A. Calverley
Christine Jenkins Australia
Marc Decramer Belgium
Suzanne S. Hurd United States
Jadwiga A. Wedzicha United Kingdom
Roberto Rodríguez-Roisin Spain
Joan B. Soriano Spain
A. Sonia Buist United States
Don D. Sin Canada
Robert A. Stockley United Kingdom
Barry J. Make United States
Christine Jenkins Australia
Peter M.A. Calverley
Citations per year, relative to Peter M.A. Calverley Peter M.A. Calverley (= 1×) peers Christine Jenkins

Countries citing papers authored by Peter M.A. Calverley

Since Specialization
Citations

This map shows the geographic impact of Peter M.A. Calverley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M.A. Calverley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M.A. Calverley more than expected).

Fields of papers citing papers by Peter M.A. Calverley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M.A. Calverley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M.A. Calverley. The network helps show where Peter M.A. Calverley may publish in the future.

Co-authorship network of co-authors of Peter M.A. Calverley

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M.A. Calverley. A scholar is included among the top collaborators of Peter M.A. Calverley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M.A. Calverley. Peter M.A. Calverley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Putcha, Nirupama, Trishul Siddharthan, Aaron Baugh, et al.. (2024). Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine. 210(11). 1300–1307. 4 indexed citations
2.
Patel, Suhani, Karl Sylvester, Zhe Wu, et al.. (2024). A comparison of respiratory oscillometry and spirometry in idiopathic pulmonary fibrosis: performance time, symptom burden and test–retest reliability. ERJ Open Research. 10(4). 227–2024. 1 indexed citations
3.
Beasley, Richard, Rod Hughes, Àlvar Agustí, et al.. (2023). Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. American Journal of Respiratory and Critical Care Medicine. 209(4). 390–401. 16 indexed citations
4.
Miravitlles, Marc, Katia Verhamme, Peter M.A. Calverley, et al.. (2022). SHILAP Revista de lepidopterología. 14 indexed citations
5.
West, Malcolm, Zacharias Anastasiou, Gareth Ambler, et al.. (2021). The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study. SHILAP Revista de lepidopterología. 1. 1–1. 5 indexed citations
6.
7.
Ritchie, Andrew I., Simon Brill, Lydia Finney, et al.. (2020). Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 202(4). 549–557. 5 indexed citations
8.
Celli, Bartolomé R., Julie A. Anderson, Nicholas J. Cowans, et al.. (2020). Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. American Journal of Respiratory and Critical Care Medicine. 203(6). 689–698. 50 indexed citations
9.
Walker, Paul, Pasquale Pio Pompilio, Paolo Zanaboni, et al.. (2018). Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 198(5). 620–628. 104 indexed citations
10.
Calverley, Peter M.A., Antonio Anzueto, Daniel Dusser, et al.. (2018). Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. International Journal of COPD. Volume 13. 1297–1308. 16 indexed citations
11.
Calverley, Peter M.A., Kay Tetzlaff, Daniel Dusser, et al.. (2017). Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. International Journal of COPD. Volume 12. 3391–3405. 35 indexed citations
12.
Dahl, Ronald, Peter M.A. Calverley, Antonio Anzueto, et al.. (2015). Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open. 5(12). e009015–e009015. 8 indexed citations
13.
Pompilio, Pasquale Pio, Valentina Isetta, Andreï Malinovschi, et al.. (2014). Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot study. European Respiratory Journal. 44(Suppl 58). P971–P971. 1 indexed citations
14.
Hanania, Nicola A., Eric Bateman, Peter M.A. Calverley, et al.. (2010). Benefits of Roflumilast Treatment on Exacerbation Outcomes in Patients With COPD: Pooled Results From Two Pivotal 12-Month Studies. CHEST Journal. 138(4). 801A–801A. 1 indexed citations
15.
Keene, Oliver N., Jørgen Vestbo, Julie A. Anderson, et al.. (2009). Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal. 34(5). 1018–1023. 22 indexed citations
16.
Stevenson, N., Paul Walker, Richard W. Costello, & Peter M.A. Calverley. (2005). Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 172(12). 1510–1516. 125 indexed citations
17.
Calverley, Peter M.A., S. I. Rennard, Àlvar Agustí, et al.. (1999). Current and future management of acute exacerbations of chronic obstructive pulmonary disease. European Respiratory Review. 9(67). 193–205. 3 indexed citations
18.
Spence, D P, Donald R. Graham, G G Jamieson, et al.. (1996). The Relationship Between Wheezing and Lung Mechanics During Methacholine-Induced Bronchoconstriction in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 154(2). 290–294. 23 indexed citations
19.
Spence, D P, Sebastian L. Johnston, Peter M.A. Calverley, et al.. (1994). The Effect of the Orally Active Platelet-Activating Factor Antagonist WEB 2086 in the Treatment of Asthma. American Journal of Respiratory and Critical Care Medicine. 149(5). 1142–1148. 69 indexed citations
20.
Calverley, Peter M.A., et al.. (1988). Heroin inhalation and asthma.. BMJ. 297(6662). 1511–1512. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine Jenkins Breakdown of academic impact, for papers by Marc Decramer Breakdown of academic impact, for papers by Suzanne S. Hurd Breakdown of academic impact, for papers by Jadwiga A. Wedzicha Breakdown of academic impact, for papers by Roberto Rodríguez-Roisin Breakdown of academic impact, for papers by Joan B. Soriano Breakdown of academic impact, for papers by A. Sonia Buist Breakdown of academic impact, for papers by Don D. Sin Breakdown of academic impact, for papers by Robert A. Stockley Breakdown of academic impact, for papers by Barry J. Make
Rankless by CCL
2026